Literature DB >> 30158277

How long is too long? A scoping review of health system delays in lung cancer.

Ashanya Malalasekera1,2, Sharon Nahm2, Prunella L Blinman2, Steven C Kao1,3, Haryana M Dhillon4, Janette L Vardy1,2,4.   

Abstract

Earlier access to lung cancer specialist (LCS) care improves survival, highlighting the need for streamlined patient referral. International guidelines recommend 14-day maximum time intervals from general practitioner (GP) referral to first LCS appointment ("GP-LCS interval"), and diagnosis to treatment ("treatment interval"). We compared time intervals in lung cancer care against timeframe benchmarks, and explored barriers and facilitators to timely care.We conducted a scoping review of literature from MEDLINE, Embase, Scopus and hand searches. Primary end-points were GP-LCS and treatment intervals. Performance against guidelines and factors responsible for delays were explored. We used descriptive statistics and nonparametric Wilcoxon rank sum tests to compare intervals in studies reporting fast-track interventions.Of 1343 identified studies, 128 full-text articles were eligible. Only 33 (26%) studies reported GP-LCS intervals, with an overall median of 7 days and distributions largely meeting guidelines. Overall, 52 (41%) studies reported treatment intervals, with a median of 27 days, and distributions of times falling short of guidelines. There was no effect of fast-track interventions on reducing time intervals. Lack of symptoms and multiple procedures or specialist visits were suggested causes for delay.Although most patients with lung cancer see a specialist within a reasonable timeframe, treatment commencement is often delayed. There is regional variation in establishing timeliness of care.
Copyright ©ERS 2018.

Entities:  

Mesh:

Year:  2018        PMID: 30158277     DOI: 10.1183/16000617.0045-2018

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  14 in total

Review 1.  Defining timeliness in care for patients with lung cancer: a scoping review.

Authors:  Adnan Ansar; Virginia Lewis; Christine Faye McDonald; Chaojie Liu; Muhammad Aziz Rahman
Journal:  BMJ Open       Date:  2022-04-07       Impact factor: 2.692

Review 2.  A systematic review of interventions to recognise, refer and diagnose patients with lung cancer symptoms.

Authors:  Mohamad M Saab; Megan McCarthy; Michelle O'Driscoll; Laura J Sahm; Patricia Leahy-Warren; Brendan Noonan; Serena FitzGerald; Maria O'Malley; Noreen Lyons; Heather E Burns; Una Kennedy; Áine Lyng; Josephine Hegarty
Journal:  NPJ Prim Care Respir Med       Date:  2022-10-18       Impact factor: 3.289

3.  The patient, diagnostic, and treatment intervals in adult patients with cancer from high- and lower-income countries: A systematic review and meta-analysis.

Authors:  Dafina Petrova; Zuzana Špacírová; Nicolás Francisco Fernández-Martínez; Ana Ching-López; Dunia Garrido; Miguel Rodríguez-Barranco; Marina Pollán; Daniel Redondo-Sánchez; Carolina Espina; Camila Higueras-Callejón; Maria José Sánchez
Journal:  PLoS Med       Date:  2022-10-20       Impact factor: 11.613

4.  Optimal Care Pathways for People with Lung Cancer- a Scoping Review of the Literature.

Authors:  Zulfiquer Otty; Amy Brown; Sabe Sabesan; Rebecca Evans; Sarah Larkins
Journal:  Int J Integr Care       Date:  2020-09-28       Impact factor: 5.120

5.  Delay to surgical treatment in lung cancer patients and its impact on survival in a video-assisted thoracoscopic lobectomy cohort.

Authors:  Florian Ponholzer; Veronika Kroepfl; Caecilia Ng; Herbert Maier; Florian Kocher; Paolo Lucciarini; Dietmar Öfner; Florian Augustin
Journal:  Sci Rep       Date:  2021-03-01       Impact factor: 4.379

6.  Time intervals and routes to diagnosis for lung cancer in 10 jurisdictions: cross-sectional study findings from the International Cancer Benchmarking Partnership (ICBP).

Authors:  Usha Menon; Peter Vedsted; David Weller; Alina Zalounina Falborg; Henry Jensen; Samantha Harrison; Irene Reguilon; Andriana Barisic; Rebecca J Bergin; David H Brewster; John Butler; Odd Terje Brustugun; Oliver Bucher; Victoria Cairnduff; Anna Gavin; Eva Grunfeld; Elizabeth Harland; Jatinderpal Kalsi; Anne Kari Knudsen; Mats Lambe; Rebecca-Jane Law; Yulan Lin; Martin Malmberg; Donna Turner; Richard D Neal; Victoria White
Journal:  BMJ Open       Date:  2019-11-27       Impact factor: 2.692

7.  The Use of Bronchoscopy During the Coronavirus Disease 2019 Pandemic: CHEST/AABIP Guideline and Expert Panel Report.

Authors:  Momen M Wahidi; Samira Shojaee; Carla R Lamb; David Ost; Fabien Maldonado; George Eapen; Daniel A Caroff; Michael P Stevens; Daniel R Ouellette; Craig Lilly; Donna D Gardner; Kristen Glisinski; Kelly Pennington; Raed Alalawi
Journal:  Chest       Date:  2020-05-01       Impact factor: 9.410

8.  EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Anne C Chiang; Ancilla W Fernandes; Melissa Pavilack; Jennifer W Wu; François Laliberté; Mei Sheng Duh; Nabil Chehab; Janakiraman Subramanian
Journal:  BMC Cancer       Date:  2020-04-28       Impact factor: 4.430

9.  Does Delaying Time in Cancer Treatment Affect Mortality? A Retrospective Cohort Study of Korean Lung and Gastric Cancer Patients.

Authors:  Kyu-Tae Han; Woorim Kim; Seungju Kim
Journal:  Int J Environ Res Public Health       Date:  2021-03-26       Impact factor: 3.390

Review 10.  Systematic Review of Interventions to Reduce Operating Time in Lung Cancer Surgery.

Authors:  Paulien C Hoefsmit; Robert J Cerfolio; Ralph de Vries; Max Dahele; H Reinier Zandbergen
Journal:  Clin Med Insights Oncol       Date:  2021-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.